# Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

- Source: PR Newswire M&A
- Published: 2026-11-03T07:35:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/moberg-pharma-granted-us-patent-relating-to-improved-dosing-of-mob-015-302927559.html
- Canonical: https://groundlevelnews.com/story/moberg-pharma-granted-u-s-patent-relating-to-improved-dosing-of-mob-01-b2e39d/

STOCKHOLM, Nov. 3, 2026 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office (USPTO) has granted a patent relating to an improved dosing regimen for MOB-015, the company's topical drug for onychomycosis. The U.S. is the first...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._